CL2021001521A1 - Compuesto agonista de receptor thrb y método de preparación y uso del mismo - Google Patents

Compuesto agonista de receptor thrb y método de preparación y uso del mismo

Info

Publication number
CL2021001521A1
CL2021001521A1 CL2021001521A CL2021001521A CL2021001521A1 CL 2021001521 A1 CL2021001521 A1 CL 2021001521A1 CL 2021001521 A CL2021001521 A CL 2021001521A CL 2021001521 A CL2021001521 A CL 2021001521A CL 2021001521 A1 CL2021001521 A1 CL 2021001521A1
Authority
CL
Chile
Prior art keywords
preparation
receptor agonist
thrb
agonist compound
compound
Prior art date
Application number
CL2021001521A
Other languages
English (en)
Inventor
Shanghai Yu
Ben Li
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of CL2021001521A1 publication Critical patent/CL2021001521A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPUESTO AGONISTA DE RECEPTOR THRΒ Y MÉTODO DE PREPARACIÓN Y USO DEL MISMO
CL2021001521A 2018-12-13 2021-06-10 Compuesto agonista de receptor thrb y método de preparación y uso del mismo CL2021001521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811527414.4A CN111320609A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CL2021001521A1 true CL2021001521A1 (es) 2022-01-28

Family

ID=71071432

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001521A CL2021001521A1 (es) 2018-12-13 2021-06-10 Compuesto agonista de receptor thrb y método de preparación y uso del mismo

Country Status (17)

Country Link
US (3) US11084802B2 (es)
EP (1) EP3893889A4 (es)
JP (1) JP2022512482A (es)
KR (1) KR20210102328A (es)
CN (3) CN111320609A (es)
AR (1) AR117694A1 (es)
AU (1) AU2019398339A1 (es)
BR (1) BR112021010871A2 (es)
CA (1) CA3120880A1 (es)
CL (1) CL2021001521A1 (es)
CO (1) CO2021008817A2 (es)
IL (2) IL283362B1 (es)
MA (1) MA54471A (es)
MX (1) MX2021006908A (es)
PE (1) PE20211788A1 (es)
SG (1) SG11202106194TA (es)
WO (1) WO2020123827A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2907926T3 (es) 2012-09-17 2022-04-27 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
CN111801324B (zh) 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
WO2020077123A1 (en) 2018-10-12 2020-04-16 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
PE20220255A1 (es) 2019-05-08 2022-02-16 Aligos Therapeutics Inc Moduladores de thr y metodos de uso de estos
CN111909137B (zh) * 2019-05-10 2023-05-30 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
CN114174282A (zh) * 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
TW202128668A (zh) * 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
CN115811972A (zh) * 2020-05-13 2023-03-17 拓臻制药公司 肝脏病症的组合治疗
CN116615416A (zh) 2020-08-25 2023-08-18 伊莱利利公司 Ssao抑制剂的多晶型物
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
CA3192169A1 (en) * 2020-09-17 2022-03-24 Sunshine Lake Pharma Co., Ltd. A compound as a thyroid hormone beta receptor agonist and use thereof
WO2022087141A1 (en) * 2020-10-23 2022-04-28 Madrigal Pharmaceuticals, Inc. Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues
US11858913B2 (en) 2020-11-06 2024-01-02 Aligos Therapeutics, Inc. Bicyclic pyridazinones and methods of use thereof
CN116925045A (zh) * 2020-12-15 2023-10-24 中国科学院上海药物研究所 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
CN114685450A (zh) 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
US20240059682A1 (en) * 2021-03-03 2024-02-22 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
TW202327589A (zh) 2021-11-11 2023-07-16 美商拓臻製藥公司 肝病之組合療法
CA3238108A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-.beta. agonist
WO2023154842A1 (en) * 2022-02-10 2023-08-17 Madrigal Pharmaceuticals, Inc. Thr beta analogs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0377903A3 (de) * 1989-01-09 1991-07-17 Bayer Ag Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
JPWO2003064369A1 (ja) * 2002-01-30 2005-05-26 キッセイ薬品工業株式会社 新規な甲状腺ホルモン受容体リガンド、それを含有する医薬組成物、およびそれらの用途
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
PL1919878T3 (pl) 2005-07-21 2011-03-31 Hoffmann La Roche Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy
KR101396606B1 (ko) 2009-04-20 2014-05-16 미쓰비시 타나베 파마 코퍼레이션 신규 갑상선 호르몬 β 수용체 작동약
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
EP3045453A1 (en) 2011-11-14 2016-07-20 Cephalon, Inc. Uracil derivatives as axl and c-met kinase inhibitors
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102898377B (zh) * 2012-02-14 2016-01-20 南京圣和药业股份有限公司 一类酞嗪酮衍生物及其用途
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
US11090308B2 (en) * 2016-10-18 2021-08-17 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a THR-beta agonist
EP3725779A4 (en) 2018-01-23 2021-02-24 Shenzhen TargetRx, Inc. SUBSTITUTED PYRIDAZINONE COMPOUND
CN111801324B (zh) * 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
CN112601674A (zh) 2018-08-24 2021-04-02 全耐塑料高级创新研究公司 包括挡板和穿过该挡板的流体输送线的流体储箱用组件
JP2021535207A (ja) 2018-08-24 2021-12-16 ターンズ・インコーポレイテッドTerns, Inc. 甲状腺ホルモン受容体ベータアゴニスト化合物
WO2020077123A1 (en) 2018-10-12 2020-04-16 Terns, Inc. Thyroid hormone receptor beta agonist compounds
JP2022504706A (ja) 2018-10-12 2022-01-13 インベンティスバイオ カンパニー リミテッド 甲状腺ホルモン受容体作動薬
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
JP7445996B2 (ja) 2019-02-21 2024-03-08 ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド 新規化合物及び甲状腺ホルモン受容体アゴニストとしてのそれらの使用
CN114174282A (zh) 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用

Also Published As

Publication number Publication date
CA3120880A1 (en) 2020-06-18
US11084802B2 (en) 2021-08-10
SG11202106194TA (en) 2021-07-29
IL310699A (en) 2024-04-01
CN113194958B (zh) 2023-05-23
IL283362A (en) 2021-07-29
KR20210102328A (ko) 2021-08-19
AR117694A1 (es) 2021-08-25
CN111320609A (zh) 2020-06-23
MX2021006908A (es) 2021-07-07
US20230278988A1 (en) 2023-09-07
CN116444498A (zh) 2023-07-18
EP3893889A1 (en) 2021-10-20
US20200399249A1 (en) 2020-12-24
MA54471A (fr) 2021-10-20
US11034676B2 (en) 2021-06-15
AU2019398339A1 (en) 2021-06-10
PE20211788A1 (es) 2021-09-09
JP2022512482A (ja) 2022-02-04
TW202039470A (zh) 2020-11-01
WO2020123827A1 (en) 2020-06-18
EP3893889A4 (en) 2022-08-03
IL283362B1 (en) 2024-03-01
US20200190064A1 (en) 2020-06-18
CN113194958A (zh) 2021-07-30
CO2021008817A2 (es) 2021-07-19
BR112021010871A2 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
CL2021001521A1 (es) Compuesto agonista de receptor thrb y método de preparación y uso del mismo
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
CL2017003486A1 (es) Lactamas bicíclicas y métodos de uso de las mismas
CL2020001452A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este.
PE20181004A1 (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CL2021003498A1 (es) Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
CL2019003557A1 (es) Anticuerpos anti-trkb.
CL2022001546A1 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
CL2018000472S1 (es) Prótesis dental
AR113867A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este
IT201700110157A1 (it) Metodo di preparazione di un agonista del recettore farnesoide x
ITUA20162272A1 (it) Procedimento per la preparazione di un agonista del recettore farnesoide x
GB201809911D0 (en) Use of trpv1 agonists
ECSP20017939A (es) Composiciones farmacéuticas